MTD-217

N/A

Report date: 2023/12/15 16:33:28
NME

Base Information

Drug NameMTD-217
Drug Alias Namepanobinostat + OXPHOS inhibitorpanobinostat + oxphosphorylation inhibitor (Biodexa Pharmaceuticals)MTD-217
ClassificationSmall molecules
Mechanisms of ActionHistone deacetylase inhibitorsMitochondrial oxidative phosphorylation inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsMeningeal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes Panobinostat Lactate
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiodexa Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesBiodexa Pharmaceuticals PLC
Inactive CompaniesN/A
Active IndicationsMeningeal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A